Document is current
Any future updates will be listed below
-
Authors
Fond, Guillaume https://orcid.org/0000-0003-3249-2030
Vidal, Martin
Joseph, Morgane
Etchecopar-Etchart, Damien https://orcid.org/0000-0002-7894-0591
Solmi, Marco https://orcid.org/0000-0003-4877-7233
Yon, Dong Keon https://orcid.org/0000-0003-1628-9948
Correll, Christoph U.
Boyer, Laurent https://orcid.org/0000-0003-1229-6622
- License Information
-
More Information
Article History
Received: 10 August 2022
Revised: 25 January 2023
Accepted: 15 February 2023
First Online: 8 March 2023
Competing interests
: CU Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma and Quantic. Marco Solmi received honoraria/has been a consultant for Angelini, Lundbeck, Otsuka. All other authors declare no competing interests.
